Japan’s public insurance to include treatment for obesity: Report

Despite concerns, Novo Nordisk claims Wegovy reduces the risk of major adverse cardiovascular events by 20%.

Last week, public medical insurance in Japan will cover Wegovy, a new obesity treatment by Novo Nordisk, marking the first inclusion of such drugs in three decades, the Japan Times reported.

The GLP-1 receptor agonist, containing semaglutide, stimulates insulin production, lowers blood sugar, induces a sense of satiety, and reduces cravings. 

READ MORE: New treatment for obesity to be covered by Japan's public insurance

Coverage is for individuals with conditions like high blood pressure, hyperlipidemia, and Type 2 diabetes, with a BMI of 35 or higher, or 27 or higher with two or more obesity-related issues. 

Concerns about potential misuse for cosmetic purposes have been raised, with Wegovy's prices tiered based on dosage.

The drug, initially designed for obesity treatment in the U.S., has seen expanded cosmetic use globally, leading to shortages and concerns about limited access for those needing it for genuine treatment. 

Japanese medical associations have expressed worries about the inappropriate use of GLP-1 drugs for non-medical purposes, such as cosmetic and diet purposes. 

Clinics offering "medical diets" have become prevalent, promoting GLP-1 diet therapy. Researchers have connected drugs like Wegovy to an increased risk of serious stomach and intestinal problems.

ALSO READ: Vietnam joins ASEAN motor insurance system for seamless cross-border travel: Report

Despite concerns, Novo Nordisk claims Wegovy reduces the risk of major adverse cardiovascular events by 20% in overweight or obese adults. 

Previously, Mazindol (Sanorex) was the only obesity treatment covered by insurance in Japan, limited due to concerns about addiction and its use restricted to three months for severe obesity cases.